IMC Chicago’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $58.7M | Buy |
421,400
+152,100
| +56% | +$21.3M | 0.02% | 448 |
|
|
2025
Q4 | $33.1M | Buy |
269,300
+17,500
| +7% | +$2.13M | 0.01% | 637 |
|
|
2025
Q3 | $27.9M | Sell |
251,800
-21,400
| -8% | -$2.43M | 0.01% | 648 |
|
|
2025
Q2 | $30.3M | Sell |
273,200
-85,500
| -24% | -$9.1M | 0.01% | 541 |
|
|
2025
Q1 | $40.2M | Buy |
358,700
+118,800
| +50% | +$12.3M | 0.02% | 376 |
|
|
2024
Q4 | $22.2M | Buy |
239,900
+15,300
| +7% | +$1.38M | 0.01% | 571 |
|
|
2024
Q3 | $18.8M | Sell |
224,600
-87,700
| -28% | -$6.69M | 0.01% | 574 |
|
|
2024
Q2 | $21.4M | Buy |
312,300
+177,300
| +131% | +$11.8M | 0.01% | 505 |
|
|
2024
Q1 | $9.89M | Buy |
135,000
+35,600
| +36% | +$2.74M | 0.01% | 709 |
|
|
2023
Q4 | $8.05M | Sell |
99,400
-18,100
| -15% | -$1.41M | 0.01% | 731 |
|
|
2023
Q3 | $8.81M | Sell |
117,500
-2,800
| -2% | -$215K | 0.01% | 586 |
|
|
2023
Q2 | $9.27M | Sell |
120,300
-98,400
| -45% | -$7.85M | 0.01% | 527 |
|
|
2023
Q1 | $18.1M | Buy |
218,700
+18,000
| +9% | +$1.49M | 0.02% | 359 |
|
|
2022
Q4 | $17.2M | Buy |
200,700
+32,000
| +19% | +$2.53M | 0.03% | 340 |
|
|
2022
Q3 | $10.4M | Sell |
168,700
-43,700
| -21% | -$2.76M | 0.01% | 430 |
|
|
2022
Q2 | $13.1M | Buy |
212,400
+52,400
| +33% | +$3.24M | 0.02% | 376 |
|
|
2022
Q1 | $9.51M | Sell |
160,000
-111,900
| -41% | -$7.15M | 0.01% | 467 |
|
|
2021
Q4 | $19.7M | Buy |
271,900
+59,800
| +28% | +$4.12M | 0.02% | 363 |
|
|
2021
Q3 | $14.8M | Buy |
212,100
+30,700
| +17% | +$2.16M | 0.02% | 422 |
|
|
2021
Q2 | $12.5M | Sell |
181,400
-171,100
| -49% | -$11.4M | 0.02% | 412 |
|
|
2021
Q1 | $22.8M | Buy |
352,500
+6,000
| +2% | +$387K | 0.03% | 265 |
|
|
2020
Q4 | $20.2M | Sell |
346,500
-91,400
| -21% | -$5.52M | 0.03% | 277 |
|
|
2020
Q3 | $27.7M | Sell |
437,900
-98,800
| -18% | -$6.85M | 0.04% | 146 |
|
|
2020
Q2 | $41.3M | Buy |
536,700
+67,600
| +14% | +$5.18M | 0.08% | 96 |
|
|
2020
Q1 | $35.1M | Buy |
469,100
+284,700
| +154% | +$19.7M | 0.07% | 82 |
|
|
2019
Q4 | $12M | Buy |
184,400
+93,200
| +102% | +$6.07M | 0.03% | 192 |
|
|
2019
Q3 | $5.78M | Sell |
91,200
-93,500
| -51% | -$6.11M | 0.02% | 264 |
|
|
2019
Q2 | $12.5M | Buy |
184,700
+56,400
| +44% | +$3.71M | 0.04% | 144 |
|
|
2019
Q1 | $8.34M | Sell |
128,300
-30,900
| -19% | -$2.05M | 0.03% | 166 |
|
|
2018
Q4 | $9.96M | Buy |
+159,200
| New | +$11.1M | 0.03% | 120 |
|
Other funds holding GILD
VCM
VPM
IMC Chicago's GILD Position: Q4 2025 in Review
IMC Chicago sold out of Gilead Sciences (GILD) in Q4 2025, closing a stake of 43,865 shares — an estimated $5.33M sold.
IMC Chicago first reported a position in GILD in Q4 2019 and held it in 12 quarters. The position peaked at $21.5M in Q4 2022. 2,215 funds tracked by Wall St. Rank hold GILD as of Q4 2025.
- IMC Chicago reported no remaining Gilead Sciences position as of Q4 2025 after selling out during the quarter.
- IMC Chicago sold 43,865 Gilead Sciences shares in Q4 2025, an estimated $5.33M.
- IMC Chicago first reported a position in Gilead Sciences in Q4 2019 and held it in 12 quarters.
- IMC Chicago's Gilead Sciences position peaked at $21.5M in Q4 2022.
- 2,215 funds tracked by Wall St. Rank held Gilead Sciences as of Q4 2025.
Based on IMC Chicago's 13F filing for Q4 2025, filed 29 Jan 2026.